PTEN公司
医学
前列腺癌
张力素
肿瘤科
前列腺
内科学
雄激素剥夺疗法
临床终点
雄激素受体
比例危险模型
比卡鲁胺
活检
泌尿科
癌
雄激素
前列腺活检
生存分析
置信区间
癌症研究
癌症
前列腺切除术
不利影响
PCA3系列
存活率
抗雄激素
临床试验
作者
Shun Sato,Yushi Suhara,Yuya Iwamoto,Kosuke Iwatani,Yu Imai,Kojiro Tashiro,Miyaka Umemori,Jun Miki,Masayuki Shimoda,Takahiro Kimura,Hiroyuki Takahashi
摘要
Abstract Background Intraductal carcinoma of the prostate (IDC-P) and phosphatase and tensin homolog (PTEN) alteration are established adverse features in prostate cancer. However, their coexistence and prognostic relevance in the era of androgen receptor pathway inhibitor (ARPI) therapy for metastatic castration-sensitive prostate cancer (mCSPC) remain unclear, particularly in Japanese populations. We evaluated the prevalence, concordance, and prognostic significance of IDC-P and PTEN loss in patients with mCSPC treated with ARPI plus androgen deprivation therapy (ADT). Methods We retrospectively analyzed consecutive patients with mCSPC who received ARPI plus ADT between February 2018 and June 2024 across three Japanese institutions. IDC-P was assessed on hematoxylin–eosin–stained biopsy specimens. PTEN loss was defined as ≥90% absence of cytoplasmic staining, consistent with the CAPItello-281 trial criteria. The primary endpoint was castration-resistant prostate cancer–free survival (CRPC-FS). Overall survival was evaluated as a secondary endpoint. Survival outcomes were assessed using Kaplan–Meier analysis and multivariable Cox regression modeling. Results In total, 121 patients were included. IDC-P was identified in 68.6% of biopsy specimens, and PTEN loss in 15.7%. Patients with IDC-P more frequently presented with CHAARTED high-volume and LATITUDE high-risk disease. During a median follow-up of 36 months, 44 patients (36.4%) developed CRPC. IDC-P was independently associated with shorter CRPC-FS [hazard ratio [HR] 2.4, 95% confidence interval (CI) 1.14–5.04; P = .02], whereas PTEN loss was not significantly associated with CRPC-FS or overall survival. Combined assessment of IDC-P and PTEN loss did not demonstrate additive prognostic value. Conclusion In this multicenter Japanese cohort, IDC-P, but not PTEN loss, independently predicted earlier progression to CRPC in patients with mCSPC treated with ARPI plus ADT. The limited overlap between IDC-P and PTEN loss suggests distinct biological mechanisms in Japanese populations. IDC-P remains a strong morphologic indicator of aggressive disease, whereas PTEN loss may serve as a therapeutic biomarker for phosphoinositide 3-kinase/AKT–targeted strategies.
科研通智能强力驱动
Strongly Powered by AbleSci AI